Last reviewed · How we verify
Tc 99m tilmanocept
At a glance
| Generic name | Tc 99m tilmanocept |
|---|---|
| Also known as | Lymphoseek, LymphoSeek |
| Sponsor | Navidea Biopharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial (PHASE2)
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) (PHASE1)
- Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA (PHASE3)
- Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept (PHASE2)
- Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA (PHASE2)
- Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH (PHASE1)
- A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tc 99m tilmanocept CI brief — competitive landscape report
- Tc 99m tilmanocept updates RSS · CI watch RSS
- Navidea Biopharmaceuticals portfolio CI